NeuroOne Medical Technologies Corp NMTC

NAS: NMTC | ISIN: US64130M2098   15/11/2024
0,711 USD (-8,96%)
(-8,96%)   15/11/2024

17 oktober 2023 · Thinking about buying stock in Faraday Future Intelligent Electric, Processa Pharmaceuticals, ZW Data Action Technologies, Neuroone Medical Technologies, or Vistagen Therapeutics? · Persbericht

16 maart 2023 · NeuroOne® Successfully Completes Initial Animal Implant of Novel Thin Film Paddle Lead for Spinal Cord Stimulation · Persbericht

9 maart 2023 · NeuroOne®#¹⁶⁰;to Participate in the 35th Annual Roth Conference · Persbericht

7 maart 2023 · NeuroOne® Awarded U.S. Patent Covering Novel and Proprietary Thin Film Electrode Platform · Persbericht

14 februari 2023 · NeuroOne® Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update · Persbericht

9 februari 2023 · NeuroOne® to Report First Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on February 14 · Persbericht

30 januari 2023 · NeuroOne® Issues Letter to Shareholders · Persbericht

22 december 2022 · NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results · Persbericht

13 december 2022 · NeuroOne® to Host Fiscal Fourth Quarter Corporate Update · Persbericht

8 december 2022 · NeuroOne® to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide Corporate Update on December 13 · Persbericht

6 december 2022 · NeuroOne® Successfully Completes Feasibility Study with its OneRF™ Ablation System · Persbericht

30 november 2022 · NeuroOne® Ships Initial Zimmer Biomet Order for its Evo® sEEG System for Less than 30 Day Use · Persbericht

22 november 2022 · NeuroOne® to Ring Nasdaq Stock Market Closing Bell on November 22 · Persbericht

21 november 2022 · NeuroOne® CEO Dave Rosa Featured on Fox Business Network's 'Mornings with Maria' · Persbericht

25 oktober 2022 · NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use · Persbericht

22 september 2022 · NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

11 augustus 2022 · NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update · Persbericht

9 augustus 2022 · NeuroOne® Submits Special 510(k) to FDA for Evo® sEEG Electrode · Persbericht

4 augustus 2022 · NeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11 · Persbericht

3 augustus 2022 · NeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode · Persbericht

Mijn selecties